Caas Capital Management LP Intra Cellular Therapies, Inc. Transaction History
Caas Capital Management LP
- $1.31 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding ITCI
# of Institutions
381Shares Held
77.7MCall Options Held
1.7MPut Options Held
1.13M-
Vanguard Group Inc Valley Forge, PA9.23MShares$642 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.08MShares$562 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$268 Million1.4% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.82MShares$196 Million3.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.48MShares$172 Million2.06% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $6.57B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...